Progress in study on apatinib in treatment of both radioactive iodine refractory and more aggressive thyroid carcinoma

doi:10.16139/j.1007-9610.2021.06.021

Abstract

CLC Number:

R736.1

ZHAN Ling, QIU Weihua. Progress in study on apatinib in treatment of both radioactive iodine refractory and more aggressive thyroid carcinoma[J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 564-567.

References 29

[30]	Feng H, Cheng X, Kuang J, et al. Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer[J]. Cell Death Dis, 2018, 9(10):1030.
[31]	Meng X, Wang H, Zhao J, et al. Apatinib inhibits cell proliferation and induces autophagy in human papillary thyroid carcinoma via the PI3K/Akt/mTOR signaling pathway[J]. Front Oncol, 2020, 10:217.
[32]	Peng QX, Han YW, Zhang YL, et al. Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma[J]. Oncotarget, 2017, 8(32):52813-52822.
[33]	Liu S, Wu F, Zhang Y, et al. Apatinib combined with radiotherapy enhances antitumor effects in an in vivo nasopharyngeal carcinoma model[J]. Cancer Control, 2020, 27(1):1073274820922553.
[34]	Li F, Zhu T, Cao B, et al. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance[J]. Eur J Cancer, 2017, 84:184-192.
[35]	Hu Y, Zhou N, Wang R. Apatinib strengthens the anti-tumor effect of cisplatin in thyroid carcinoma through downregulating VEGFR2[J]. J BUON, 2021, 26(2):613-619.
[36]	Tong XZ, Wang F, Liang S, et al. Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells[J]. Biochem Pharmacol, 2012, 83(5):586-597.
[37]	Mi YJ, Liang YJ, Huang HB, et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters[J]. Cancer Res, 2010, 70(20):7981-7991.
[1]	Jin Y, van Nostrand D, Cheng L, et al. Radioiodine refractory differentiated thyroid cancer[J]. Crit Rev Oncol Hematol, 2018, 125:111-120.
[2]	Cai S, Deng H, Chen Y, et al. Treatment of medullary thyroid carcinoma with apatinib: a case report and literature review[J]. Medicine (Baltimore), 2017, 96(50):e8704.
[3]	Cheng L, Jiao Q, Jin Y, et al. Initial therapy of advanced anaplastic thyroid cancer via targeting VEGFR-2: a case report[J]. Onco Targets Ther, 2019, 12:10495-10500.
[4]	Ibrahimpasic T, Ghossein R, Shah JP, et al. Poorly differentiated carcinoma of the thyroid gland: current status and future prospects[J]. Thyroid, 2019, 29(3):311-321.
[5]	Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers[J]. J Clin Endocrinol Metab, 2009, 94(5):1493-1499.
[6]	Guleng B, Tateishi K, Ohta M, et al. Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner[J]. Cancer Res, 2005, 65(13):5864-5871.
[7]	Klein M, Picard E, Vignaud JM, et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma[J]. J Endocrinol, 1999, 161(1):41-49.
[8]	Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial[J]. Lancet, 2014, 384(9940):319-328.
[9]	Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med, 2015, 372(7):621-630.
[10]	Li J, Qin S, Xu J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase Ⅱtrial[J]. J Clin Oncol, 2013, 31(26):3219-3225.
[11]	Xiao J, Liang J, Zhang W, et al. Clinical observation of apatinib-related hypothyroidism in patients with advanced malignancies[J]. Exp Ther Med, 2020, 20(3):1961-1966.
[12]	Scott LJ. Apatinib: a review in advanced gastric cancer and other advanced cancers[J]. Drugs, 2018, 78(7):747-758.
[13]	Zhou Y, Zhang W, Tang F, et al. A case report of apatinib in treating osteosarcoma with pulmonary metastases[J]. Medicine (Baltimore), 2017, 96(15):e6578.
[14]	Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase Ⅱtrial[J]. Clin Cancer Res, 2021, 27(4):1003-1011.
[15]	Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase Ⅲtrial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J]. J Clin Oncol, 2016, 34(13):1448-1454.
[16]	Zhang S. Problematic analysis and inadequate toxicity data in phase Ⅲapatinib trial in gastric cancer[J]. J Clin Oncol, 2016, 34(31):3821.
[17]	Hu X, Cao J, Hu W, et al. Multicenter phase Ⅱstudy of apatinib in non-triple-negative metastatic breast cancer[J]. BMC Cancer, 2014, 14:820.
[18]	Wu F, Zhang S, Xiong A, et al. A phase Ⅱclinical trial of apatinib in pretreated advanced non-squamous non-small-cell lung cancer[J]. Clin Lung Cancer, 2018, 19(6):e831-e842.
[19]	Zhang Y, Deng X, Ding Z, et al. Preoperative neoadjuvant targeted therapy with apatinib for inoperable diffe-rentiated thyroid cancer: a case report[J]. Medicine (Baltimore), 2021, 100(12):e25191.
[20]	Lin Y, Wang C, Gao W, et al. Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer[J]. Oncotarget, 2017, 8(26):42252-42261.
[21]	Chen K, Gao Y, Shi F, et al. Apatinib-treated advanced medullary thyroid carcinoma: a case report[J]. Onco Targets Ther, 2018, 11:459-463.
[22]	Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Sta-ging System for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why?[J]. Thyroid, 2017, 27(6):751-756.
[23]	Sugitani I, Miyauchi A, Sugino K, et al. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients[J]. World J Surg, 2012, 36(6):1247-1254.
[24]	De Crevoisier R, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2004, 60(4):1137-1143.
[25]	Niu Y, Ding Z, Deng X, et al. A novel multimodal therapy for anaplastic thyroid carcinoma: ¹²⁵I seed implantation plus apatinib after surgery[J]. Front Endocrinol (Lausanne), 2020, 11:207.
[26]	Chen W, Li Z, Zheng Z, et al. Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: a single-center retrospective study[J]. Cancer Med, 2020, 9(16):5899-5907.
[27]	Lin YS, Zhang X, Wang C, et al. Long-term results of phase Ⅱtrial of apatinib for progressive radioiodine refractory differentiated thyroid cancer[J]. J Clin Endocrinol Metab, 2021, 106(8):e3027-e3036.
[28]	Zhang X, Wang C, Lin Y. Pilot dose comparison of apatinib in Chinese patients with progressive radioiodine-refractory differentiated thyroid cancer[J]. J Clin Endocrinol Metab, 2018, 103(10):3640-3646.
[29]	Jin Z, Cheng X, Feng H, et al. Apatinib inhibits angiogenesis via suppressing Akt/GSK3β/ANG signaling pathway in anaplastic thyroid cancer[J]. Cell Physiol Biochem, 2017, 44(4):1471-1484.

Progress in study on apatinib in treatment of both radioactive iodine refractory and more aggressive thyroid carcinoma

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 29

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	HE Wen, GU Jianhua, XING Xujian, WENG Ziyi, FEI Jian. Tracheal diverticula discovered during surgery: a report of 2 cases and literature review [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 383-387.
[2]	KONG Weiqi, HE Jun, YANG Chengguang, LIU Weiwei, XU Yingjie. Pheochromocytoma with papillary thyroid carcinoma: one case report [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 162-165.
[3]	YAN Haibo, XIA Zhongping, CHEN Shan, JIANG Lin, HAN Chun. Risk factors for Delphian lymph node metastasis in papillary thyroid carcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 453-457.
[4]	LI Rui, LIU Zhuoran, YAN Jiqi. Progress of study on medullary thyroid carcinoma with serum calcitonin-negative and large mass [J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 271-275.
[5]	CHEN Chengkun, GUO Bomin, DENG Xianzhao, WU Bo, FAN Youben. Diagnosis and treatment of medullary thyroid carcinoma-an update [J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 276-280.
[6]	WU Chunxiao, GU Kai, PANG Yi, BAO Pingping, WANG Chunfang, SHI Liang, XIANG Yongmei, GONG Yangming, DOU Jianming, WU Mengyin, FU Chen, SHI Yan. Thyroid cancer incidence and mortality in Shanghai China 2016 and trends from 2002 to 2016 [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 58-65.
[7]	LIU Rongyao, LI Xiangcui, WANG Lina, CHEN Haizhen. Analysis of risk factors for cervical lymph node metastasis in papillary thyroid carcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 76-79.
[8]	FAN Jinfang, SHEN Yi, ZHAN Weiwei, TAO Lingling, LI Weiwei, KUANG Lijun, ZHOU Wei. Clinicopathological analysis of papillary thyroid microcarcinoma in isthmus [J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 528-531.
[9]	ZHANG Gang, ZHANG Zhe, ZHANG Shu, LI Zhirong, TIAN Wuguo, HUANG Qi, WANG Lingli, XU Yan. Association between RET genotype and disease phenotype in patients with hereditary medullary thyroid carcinoma [J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 522-527.
[10]	SUN Hanxing, SHEN Xiaohui, GAO Haoji, LIU Zhuoran, CHEN Xi, QIU Weihua, YAN Jiqi. Preoperative evaluation and preparation of Graves′ disease: a report of 126 cases [J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 517-521.
[11]	YAN Shouyi, CHEN Hongbin, ZHANG Liyong, WANG Bo, CAI Shaojun, LIN Siying, ZHAO Wenxin. Retrospective study on Bethesda Ⅴ thyroid nodule in diagnosis of papillary thyroid carcinoma: retrospective study [J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 512-516.
[12]	TANG Juan, LIU Zhiyan. [J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 504-509.
[13]	WANG Zhuoying, SHI Yuan, GUO Kai, QIAN Kai. Making strange new norm: clinical approaches to children andadolescent with differentiated thyroid carcinoma [J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 497-499.
[14]	HUANG Naisi, CHEN Jiaying, Jl Qinghai, QANG Yu. New adjuvant treatment of locally advanced thyroid carcinoma in era of targeted therapy [J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 493-496.
[15]	WANG Xudong. Interpretation of more aggressive papillary thyroid microcarcinoma [J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 486-492.